April 3, 2019Clinical Cancer Research
The Intersection between Tumor Angiogenesis and Immune Suppression
Authors
Discussion
Loading...
Member takes
Implication
Review demonstrates reciprocal cross-talk between vascular growth and immunosuppression in tumors, highlighting clinical benefits of combining antiangiogenic agents with checkpoint inhibitors.
Key Points
- To examine the biological mechanisms connecting tumor angiogenesis with immune suppression and evaluate therapeutic strategies combining antiangiogenic agents with immune checkpoint inhibitors.
- Synthesized molecular and cellular mechanisms linking proangiogenic signaling pathways to immune evasion in the tumor microenvironment.
- Evaluated translational and clinical evidence supporting combination regimens of antiangiogenic agents and immune checkpoint inhibitors across solid tumors.
- Angiogenic factors directly inhibit antigen-presenting cells and effector lymphocytes while augmenting suppressive cell populations, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages.
- Suppressive immune cells conversely promote neovascularization, establishing a self-reinforcing vicious cycle that mediates resistance to immune checkpoint blockade.
- Combination regimens targeting both vascular endothelial growth pathways and immune checkpoints, beginning with bevacizumab plus ipilimumab, show enhanced clinical activity in noninflamed tumors.
Cite This Study
Rahma et al. (2019) studied this question.